For the third year in a row, we organized the CureDRPLA Research Conference in Boston to bring together scientists funded by us, healthcare professionals and representatives of pharmaceutical companies. At these meetings, we review the past year’s progress and invite...

CureDRPLA was founded in November 2019 and in light of our forthcoming founding anniversary, we have prepared an impact report to summarize our work and milestones. In this report you will find a summary of our achievements to date and our goals for the next 5 years....

Last week, Dr Silvia Prades attended a conference to find out more about the latest work on rare diseases and how the medicines regulatory framework is expected to change in the coming years to facilitate research and approval of treatments for rare conditions like...

CureDRPLA co-founders, Paul and Andrea Compton, have a son with DRPLA and their personal experiences with this devastating condition are the driving force behind CureDRPLA. Earlier this year, CureDRPLA announced that n-Lorem had an experimental treatment for DRPLA and...

Nissan Chemical Corporation and Sanwa Kagaku Kenkyusho Co., Ltd., two Japanese companies, have announced they recently co-created an antisense oligonucleotide (ASO) for DRPLA. ASOs have emerged as a promising strategy for various neurodegenerative conditions,...